Myobloc (Diacerein)

Diacerein blocks the activity of interleukin‑1, a cytokine that promotes inflammation and cartilage degradation. By inhibiting this pathway, the drug reduces the production of enzymes that damage joint cartilage, thereby decreasing pain and slowing disease progression.

The dosage of Myobloc is determined by the prescribing clinician based on the patient’s condition, age, and overall health. Healthcare professionals set the appropriate dose and schedule according to current clinical guidelines.

Safety data for diacerein in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Myobloc product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Unlike conventional NSAIDs that mainly provide pain relief, Myobloc (diacerein) is a disease‑modifying osteoarthritis drug that targets inflammatory pathways and cartilage degradation. This mechanism may offer longer‑term joint protection, though safety profiles differ and treatment choice should be individualized.

Myobloc should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture. Keep the product away from direct sunlight and out of reach of children to maintain its stability and efficacy.

Myobloc is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include liver enzyme elevation, severe allergic reactions such as Stevens‑Johnson syndrome, and rare blood disorders. Patients should be monitored for signs of hepatic dysfunction, skin reactions, or abnormal blood counts and seek medical attention promptly if they occur.

Myobloc is contraindicated in individuals with known hypersensitivity to diacerein or any of its excipients, active gastrointestinal ulcer disease, and patients with severe liver impairment. Clinicians should evaluate each patient’s medical history before prescribing.